

Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2026-2034

<https://marketpublishers.com/r/A6AA17097A66EN.html>

Date: March 2026

Pages: 135

Price: US\$ 3,999.00 (Single User License)

ID: A6AA17097A66EN

Abstracts

The global allergy immunotherapies market size was valued at USD 3.7 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 7.6 Billion by 2034, exhibiting a CAGR of 8.21% from 2026-2034. Europe currently dominates the market, holding an allergy immunotherapies market share of over 48.4% in 2025. The market is propelled by the rising prevalence of allergic conditions, increasing awareness about immunotherapy as an effective treatment for allergies, significant developments in immunotherapy treatments and technologies, favorable government policies and funding for allergy research, and customized medicine and tailored treatment approaches.

A major driver in the allergy immunotherapies market is the rising prevalence of allergic disorders globally. Factors such as increasing pollution levels, climate change, and changing lifestyles have contributed to a surge in conditions like allergic rhinitis, asthma, and food allergies. This growing patient pool has heightened the demand for effective long-term treatment solutions beyond symptomatic relief. Immunotherapies, including subcutaneous and sublingual options, offer sustained benefits by desensitizing the immune system. Additionally, advancements in biologics and improved diagnostic tools are driving treatment adoption, while increased awareness and favorable reimbursement policies further supporting the allergy immunotherapies market growth.

The U.S. allergy immunotherapies market is driven by a high prevalence of allergic conditions, including allergic rhinitis, asthma, and food allergies with a share of 83.50%. Rising environmental pollution, genetic predisposition, and lifestyle factors contribute to increasing cases. The market benefits from strong healthcare infrastructure, advanced diagnostic capabilities, and ongoing research into novel biologic therapies. Growing

adoption of sublingual immunotherapy (SLIT) and regulatory approvals for innovative treatments enhance allergy immunotherapies market demand. Additionally, increased awareness among patients and physicians, along with favorable insurance coverage, supports treatment accessibility. The presence of key pharmaceutical companies investing in immunotherapy advancements further strengthens the U.S. market landscape.

ALLERGY IMMUNOTHERAPIES MARKET TRENDS:

Increasing Incidence of Allergic Disorders

The global increase in the prevalence of allergic diseases is a major driver of the allergy immunotherapies market. Allergies, such as allergic rhinitis, asthma, and food allergies, have become more common worldwide, particularly in industrialized countries. Environmental factors, such as pollution and changes in lifestyle and dietary habits, have contributed to this increase. According to the World Health Organization (WHO), asthma affected almost 262 Million individuals in 2019 and caused 455,000 deaths. This growing patient population demands effective long-term treatment solutions, thereby boosting the demand for allergy immunotherapies which promise desensitization to allergens and a potential reduction in the severity of allergic reactions.

Significant Advancements in Treatment Technologies

Technological advancements in allergy immunotherapies have revolutionized the approach and effectiveness of treatments for allergic diseases. Innovations such as peptide-based immunotherapies and recombinant allergens mark a significant departure from traditional methods, offering a more personalized and precise treatment pathway. Peptide-based therapies, for instance, utilize small peptides that represent parts of the allergen proteins to induce tolerance without triggering a full immune response, thereby minimizing the risk of severe reactions that are sometimes seen with whole-allergen immunotherapies. According to the IMARC GROUP, the global peptide therapeutics market has reached USD 42.8 Billion in 2023, and is projected to reach USD 86.9 Billion by 2032, exhibiting a CAGR of 7.9% during 2024-2032. Similarly, recombinant allergens, which are genetically engineered to mimic natural allergens, provide a purer and more consistent treatment option that can be finely tuned for dosage and formulation. These technological breakthroughs have improved the safety profile of immunotherapies and have also enhanced their efficacy, leading to higher success rates in desensitizing patients to allergens.

Regulatory and Reimbursement Landscape

The regulatory and reimbursement landscape plays a crucial role in shaping the allergy immunotherapies market, significantly influencing both the development and the widespread adoption of new treatments. Recent years have seen a positive trend in this regard, with regulatory bodies such as the U.S. Food and Drug Administration (FDA) granting approvals to innovative treatments such as sublingual immunotherapy tablets. These approvals are pivotal because they validate the safety and efficacy of new therapies and facilitate broader market access. Concurrently, there has been a marked improvement in insurance coverage for these therapies. This expansion in coverage is crucial for patients, as it alleviates the financial burden associated with long-term allergy management, making these advanced therapies more feasible for a larger number of individuals.

ALLERGY IMMUNOTHERAPIES INDUSTRY SEGMENTATION:

IMARC Group provides an analysis of the key trends in each segment of the global allergy immunotherapies market, along with forecast at the global, regional, and country levels from 2026-2034. The market has been categorized based on treatment type, allergy type, and distribution channel.

Analysis by Treatment Type:

Subcutaneous Immunotherapy (SCIT)

Sublingual Immunotherapy (SLIT)

Subcutaneous immunotherapy (SCIT) dominates the allergy immunotherapies market with a significant share of 69% due to its well-established efficacy in providing long-term relief from allergic conditions, particularly allergic rhinitis and asthma. SCIT involves controlled allergen exposure through injections, gradually desensitizing the immune system. Its widespread adoption is driven by strong clinical evidence, physician preference, and higher patient adherence compared to other methods. Despite requiring frequent clinic visits, SCIT remains a preferred option due to its proven ability to modify disease progression. Advancements in formulation and dosing strategies enhance its safety and effectiveness. Additionally, favorable reimbursement policies and regulatory approvals further support SCIT's strong market presence.

Analysis by Allergy Type:

Allergic Rhinitis

Asthma

Food Allergy

Venom Allergy

Others

Allergic rhinitis holds the largest share of 45.3% in the allergy immunotherapies industry due to its high global prevalence and significant impact on quality of life. Factors such as increasing environmental pollution, seasonal pollen exposure, and genetic susceptibility contribute to rising cases. The chronic nature of the condition drives demand for long-term treatment options beyond antihistamines and corticosteroids. Immunotherapies, including subcutaneous and sublingual treatments, provide sustained relief by modifying immune responses. Advancements in targeted therapies and increased awareness among patients and healthcare providers further support market dominance. Favorable reimbursement policies and growing clinical research into innovative treatments continue to drive the allergy immunotherapies market outlook.

Analysis by Distribution Channel:

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Hospital pharmacies lead the allergy immunotherapies market share, accounting for 42% due to their role in providing specialized treatments. These pharmacies ensure access to subcutaneous immunotherapy (SCIT) and biologic therapies, which require professional administration and monitoring. The controlled hospital environment enhances patient safety, adherence, and treatment efficacy. Additionally, hospital pharmacies benefit from favorable reimbursement policies and streamlined procurement

processes, ensuring consistent availability of immunotherapy products. The rising prevalence of severe allergic conditions, particularly asthma and anaphylaxis, further drives demand for hospital-based treatment. Advanced diagnostic capabilities in hospitals also support accurate allergy management, reinforcing their dominance in the market.

Regional Analysis:

Europe

North America

Asia Pacific

Middle East and Africa

Latin America

According to the allergy immunotherapies market forecast, Europe leads the allergy immunotherapies market with a share of 48.4% due to a high prevalence of allergic conditions, well-established healthcare infrastructure, and strong regulatory support. Rising cases of allergic rhinitis and asthma, driven by environmental pollution and climate change, boost demand for effective long-term treatments. The region has widespread adoption of both subcutaneous (SCIT) and sublingual (SLIT) immunotherapies, supported by favorable reimbursement policies and physician awareness. Ongoing research, clinical advancements, and regulatory approvals for innovative biologic therapies further strengthen Europe's market position. Additionally, increasing patient awareness, a strong presence of pharmaceutical companies, and government initiatives promoting allergy treatments contribute to market leadership. Europe's focus on personalized medicine and advanced diagnostics further enhances immunotherapy adoption.

KEY REGIONAL TAKEAWAYS:

NORTH AMERICA ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

The North America allergy immunotherapy market is experiencing continued growth, with a rising incidence of allergies and a growing emphasis on long-term therapy.

Immunotherapy, including subcutaneous (SCIT) and sublingual (SLIT) therapy, is increasingly popular with its established efficacy to reduce allergic reactions and improve patient quality of life. The growth of awareness around personalized medicine and increases in biologic use are also driving reform in this area. Clearances and ongoing work on emerging treatments, such as peptide vaccines and recombinant allergens, are growing therapy options. Expanding healthcare expenditure and enhanced diagnostics are also elevating accessibility of immunotherapy products. However, challenges such as prohibitive expense, extent limitation under cover, and compliance factors still block full-scale usage. Pharma firms and clinicians are focusing on patient education and innovative delivery formats to improve compliance. With expanding research and collaborative efforts with industries, the North American allergy immunotherapy market will continue to expand.

UNITED STATES ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Driving factors of allergy immunotherapies in the United States are significantly influenced by growing investments in healthcare sectors, leading to enhanced research, development, and accessibility of advanced treatment options. According to reports, in the US pharmaceutical industry, there were 25 private equity deals announced in Q3 2024, worth a total value of USD 2.3 Billion. The expanding healthcare infrastructure, supported by both public and private investments, has facilitated the introduction of novel therapies aimed at managing allergic conditions effectively. Rising awareness among patients and healthcare professionals about allergy immunotherapies has contributed to increased adoption, further supported by funding in clinical trials and regulatory advancements. The integration of precision medicine and biopharmaceutical innovations has accelerated the availability of personalized treatments, aligning with the demand for targeted allergy solutions. Market expansion is also driven by increasing collaborations between pharmaceutical companies and research institutions, ensuring continuous advancements in immunotherapy formulations. The growing focus on patient-centric approaches, coupled with healthcare policy reforms, has created a conducive environment for the adoption of allergy immunotherapies.

ASIA PACIFIC ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Growing allergy immunotherapies adoption due to growing online pharmacy in Asia-pacific is reshaping accessibility and affordability, expanding patient reach through digital platforms. According to India Brand Equity Foundation, India's e-commerce platforms achieved a significant milestone, hitting a GMV of USD 60 Billion in fiscal year 2023, marking a 22% increase from the previous year. The rapid expansion of e-

commerce-driven pharmaceutical distribution networks is enabling convenient access to immunotherapy products, eliminating geographical limitations. The increasing adoption of telemedicine is facilitating virtual consultations, enhancing prescription accessibility, and promoting patient adherence. Rising internet penetration and digital health awareness are driving consumer preference for online medication procurement, streamlining the supply chain. Competitive pricing strategies among online pharmacy providers are improving affordability, encouraging broader adoption. Regulatory support for digital healthcare infrastructure is fostering transparency and credibility, ensuring the safe distribution of allergy immunotherapies. Growing partnerships between pharmaceutical manufacturers and online pharmacy platforms are optimizing supply chain efficiency, accelerating product availability. The continuous technological advancements in online healthcare services are strengthening consumer confidence, further driving the market growth of allergy immunotherapies in Asia-pacific.

EUROPE ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Growing allergy immunotherapies adoption due to growing aging population in Europe is intensifying the demand for long-term allergy management solutions, as older individuals exhibit heightened sensitivity to allergens. According to WHO, the population aged 60 and older is rapidly growing in the WHO European Region. In 2021, there were 215 Million; by 2030, it is projected to be 247 Million, and by 2050, over 300 Million. Age-related immune system changes are increasing the prevalence of allergic conditions, necessitating sustained immunotherapy treatments. The rising burden of chronic respiratory allergies among aging individuals is propelling the need for advanced treatment options, fostering the integration of allergy immunotherapies into routine geriatric care. Expanding healthcare initiatives targeting the aging population are promoting early diagnosis and intervention, enhancing treatment effectiveness. Increased governmental healthcare expenditure is strengthening research initiatives, leading to improved therapeutic innovations. Growing awareness of age-related allergic complications is encouraging proactive healthcare approaches, fostering widespread immunotherapy acceptance. The rising emphasis on preventive healthcare for aging individuals is bolstering demand, ensuring sustained market expansion. The continuous evolution of geriatric-focused treatment protocols is facilitating broader accessibility and adoption of allergy immunotherapies in Europe.

LATIN AMERICA ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Growing allergy immunotherapies adoption due to growing privatization in healthcare in Latin America is enhancing treatment accessibility and innovation, driving increased

investment in advanced allergy management solutions. According to the Brazilian Federation of Hospitals (FBH) and the National Confederation of Health (CNSa?de), of Brazil's 7,191 hospitals, 62% are private. Expanding private healthcare infrastructure is promoting high-quality medical services, encouraging the adoption of allergy immunotherapies. The rising presence of specialized allergy clinics within the private sector is fostering early diagnosis and personalized treatment plans, improving patient outcomes. Increased collaboration between private healthcare providers and pharmaceutical companies is accelerating immunotherapy development and market penetration. Competitive pricing models within privatized healthcare systems are improving affordability, facilitating wider treatment adoption. The growing preference for premium healthcare services among urban populations is further supporting immunotherapy integration.

MIDDLE EAST AND AFRICA ALLERGY IMMUNOTHERAPIES MARKET ANALYSIS

Increased adoption of allergy immunotherapies because of increased medical facilities in Africa and the Middle East is fueling market growth through enhanced accessibility and quality of healthcare services. As per Dubai Healthcare City Authority report, Dubai's healthcare industry experienced rapid expansion, with 4,482 private medical centers and 55,208 licensed professionals in 2022, which is expected to grow further by 3-6% in facilities and 10-15% in professionals in 2023. The ongoing development of new-age hospitals and specialized allergy treatment centers is promoting early diagnosis and focused immunotherapy solutions. Growing investments in the healthcare infrastructure are boosting medical research capacity, backing the growth of sophisticated immunotherapy treatments. Growth in the presence of skilled healthcare workers who focus on managing allergy is promoting increasing immunotherapy usage. Increasing availability of diagnostic tools is enhancing detection of allergy, encouraging timely intervention.

COMPETITIVE LANDSCAPE:

The market competition of allergy immunotherapies is defined by pharmaceutical companies that are specialized in developing innovative solution forms. The players compete on the effectiveness of the product, delivery form, and long-term value. The R&D activities are generating new high-tech biologics and new forms of immunotherapy, increasing treatment choices. Regulatory clearances are important drivers of competition as companies strive to differentiate on compliance and clinical progress. Players also focus on strategic partnerships, mergers, and acquisitions to strengthen portfolios. Increasing use of sublingual therapy and injectable

immunotherapy drives competition with intense focus on convenience for the patient and enhanced therapeutic benefits. Pricing and reimbursement strategies also impact market positioning.

The report provides a comprehensive analysis of the competitive landscape in the allergy immunotherapies market with detailed profiles of all major companies, including:

ALK-Abello A/S

Allergy Therapeutics

Stallergenes Greer

HAL Allergy Holding B.V.

DBV Technologies

Merck KGaA

Aimmune Therapeutics

Circassia Pharmaceuticals

Anergis SA

Biomay AG

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the allergy immunotherapies market?
2. What is the future outlook of allergy immunotherapies market?
3. What are the key factors driving the allergy immunotherapies market?
4. Which region accounts for the largest allergy immunotherapies market share?
5. Which are the leading companies in the global allergy immunotherapies market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL ALLERGY IMMUNOTHERAPIES MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Breakup by Treatment Type
- 5.5 Market Breakup by Allergy Type
- 5.6 Market Breakup by Distribution Channel
- 5.7 Market Breakup by Region
- 5.8 Market Forecast

6 MARKET BREAKUP BY TREATMENT TYPE

- 6.1 Subcutaneous Immunotherapy (SCIT)
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast

6.2 Sublingual Immunotherapy (SLIT)

6.2.1 Market Trends

6.2.2 Market Forecast

7 MARKET BREAKUP BY ALLERGY TYPE

7.1 Allergic Rhinitis

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Asthma

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Food Allergy

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Venom Allergy

7.4.1 Market Trends

7.4.2 Market Forecast

7.5 Others

7.5.1 Market Trends

7.5.2 Market Forecast

8 MARKET BREAKUP BY DISTRIBUTION CHANNEL

8.1 Hospital Pharmacy

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Retail Pharmacy

8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Online Pharmacy

8.3.1 Market Trends

8.3.2 Market Forecast

9 MARKET BREAKUP BY REGION

9.1 Europe

9.1.1 Market Trends

9.1.2 Market Forecast

9.2 North America

9.2.1 Market Trends

9.2.2 Market Forecast

9.3 Asia Pacific

9.3.1 Market Trends

9.3.2 Market Forecast

9.4 Middle East and Africa

9.4.1 Market Trends

9.4.2 Market Forecast

9.5 Latin America

9.5.1 Market Trends

9.5.2 Market Forecast

10 SWOT ANALYSIS

10.1 Overview

10.2 Strengths

10.3 Weaknesses

10.4 Opportunities

10.5 Threats

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 PRICE ANALYSIS

13.1 Price Indicators

13.2 Price Structure

13.3 Margin Analysis

14 COMPETITIVE LANDSCAPE

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

14.3.1 ALK-Abello A/S

14.3.2 Allergy Therapeutics

14.3.3 Stallergenes Greer

14.3.4 HAL Allergy Holding B.V.

14.3.5 DBV Technologies

14.3.6 Merck KGaA

14.3.7 Aimmune Therapeutics

14.3.8 Circassia Pharmaceuticals

14.3.9 Anergis SA

14.3.10 Biomay AG

List Of Tables

LIST OF TABLES

Table 1: Global: Allergy Immunotherapies Market: Key Industry Highlights, 2025 and 2034

Table 2: Global: Allergy Immunotherapies Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034

Table 3: Global: Allergy Immunotherapies Market Forecast: Breakup by Allergy Type (in Million USD), 2026-2034

Table 4: Global: Allergy Immunotherapies Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034

Table 5: Global: Allergy Immunotherapies Market Forecast: Breakup by Region (in Million USD), 2026-2034

Table 6: Global: Allergy Immunotherapies Market Structure

Table 7: Global: Allergy Immunotherapies Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Allergy Immunotherapies Market: Major Drivers and Challenges

Figure 2: Global: Allergy Immunotherapies Market: Sales Value (in Billion USD), 2020-2025

Figure 3: Global: Allergy Immunotherapies Market: Breakup by Treatment Type (in %), 2025

Figure 4: Global: Allergy Immunotherapies Market: Breakup by Allergy Type (in %), 2025

Figure 5: Global: Allergy Immunotherapies Market: Breakup by Distribution Channel (in %), 2025

Figure 6: Global: Allergy Immunotherapies Market: Breakup by Region (in %), 2025

Figure 7: Global: Allergy Immunotherapies Market Forecast: Sales Value (in Billion USD), 2026-2034

Figure 8: Global: Allergy Immunotherapies Industry: SWOT Analysis

Figure 9: Global: Allergy Immunotherapies Industry: Value Chain Analysis

Figure 10: Global: Allergy Immunotherapies Industry: Porter's Five Forces Analysis

Figure 11: Global: Allergy Immunotherapies (Subcutaneous Immunotherapy) Market: Sales Value (in Million USD), 2020 & 2025

Figure 12: Global: Allergy Immunotherapies (Subcutaneous Immunotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 13: Global: Allergy Immunotherapies (Sublingual Immunotherapy) Market: Sales Value (in Million USD), 2020 & 2025

Figure 14: Global: Allergy Immunotherapies (Sublingual Immunotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 15: Global: Allergy Immunotherapies (Allergic Rhinitis) Market: Sales Value (in Million USD), 2020 & 2025

Figure 16: Global: Allergy Immunotherapies (Allergic Rhinitis) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 17: Global: Allergy Immunotherapies (Asthma) Market: Sales Value (in Million USD), 2020 & 2025

Figure 18: Global: Allergy Immunotherapies (Asthma) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 19: Global: Allergy Immunotherapies (Food Allergy) Market: Sales Value (in Million USD), 2020 & 2025

Figure 20: Global: Allergy Immunotherapies (Food Allergy) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 21: Global: Allergy Immunotherapies (Venom Allergy) Market: Sales Value (in

Million USD), 2020 & 2025

Figure 22: Global: Allergy Immunotherapies (Venom Allergy) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 23: Global: Allergy Immunotherapies (Other Allergy Types) Market: Sales Value (in Million USD), 2020 & 2025

Figure 24: Global: Allergy Immunotherapies (Other Allergy Types) Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 25: Global: Allergy Immunotherapies Market: Sales through Hospital Pharmacy (in Million USD), 2020 & 2025

Figure 26: Global: Allergy Immunotherapies Market Forecast: Sales through Hospital Pharmacy (in Million USD), 2026-2034

Figure 27: Global: Allergy Immunotherapies Market: Sales through Retail Pharmacy (in Million USD), 2020 & 2025

Figure 28: Global: Allergy Immunotherapies Market Forecast: Sales through Retail Pharmacy (in Million USD), 2026-2034

Figure 29: Global: Allergy Immunotherapies Market: Online Sales (in Million USD), 2020 & 2025

Figure 30: Global: Allergy Immunotherapies Market Forecast: Online Sales (in Million USD), 2026-2034

Figure 31: Europe: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025

Figure 32: Europe: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 33: North America: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025

Figure 34: North America: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 35: Asia Pacific: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025

Figure 36: Asia Pacific: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 37: Middle East and Africa: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025

Figure 38: Middle East and Africa: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034

Figure 39: Latin America: Allergy Immunotherapies Market: Sales Value (in Million USD), 2020 & 2025

Figure 40: Latin America: Allergy Immunotherapies Market Forecast: Sales Value (in Million USD), 2026-2034

I would like to order

Product name: Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2026-2034

Product link: <https://marketpublishers.com/r/A6AA17097A66EN.html>

Price: US\$ 3,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A6AA17097A66EN.html>